EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient

Abstract

Authors

E.C.H. Tan M.C. Yang

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×